The global EnzymeLinked Immunosorbent Assay (ELISA) Market, by Method (Direct ELISA,Indirect ELISA, Sandwich ELISA, and Competitive ELISA), by Application (VaccineDevelopment, Immunology, Diagnostics, Toxicology, Drug Monitoring &Pharmaceutical Industry & Transplantation), By Technology(Chemiluminescent, Colorimetric, & Fluorescent), and by Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa) wasvalued at US$ 1,583.4 million in 2016 and is projected to exhibit a CAGR of5.1% over the forecast period (2017 – 2025). Enzyme-Linked Immunosorbent Assay(ELISA) Market is expected to gain significant traction over the forecastperiod, owing to the launch of novel assays and increasing demand for costefficient tools due to increasing incidence of chronic infectious diseases andcancer. For instance, According to a National Cancer Institute, 2016, anestimated 16.8 million new cases of cancer were diagnosed in the U.S., witharound 595,690 deaths from the disease. The number of people suffering fromcancer is expected to rise to 19 million by 2024.
Technological advancements inELISA test kits are expected to foster growth of global Enzyme Linked ImmunosorbentAssay (ELISA) Market Extensive research and development in the field ofimmunoassay and diagnostics is leading to increasing applications and novelapproaches for incorporation of ELISA in various medical fields. This hasresulted in expansion of the range of Enzyme Linked Immunosorbent Assay (ELISA)products used in clinical and medical approaches. For instance, InovaDiagnostics, in November 2016, received U.S. FDA approval for QUANTA Lite, aCalprotectin Extended range of quantitative ELISA assay that aids in thediagnosis of Inflammatory Bowel Disease (IBD) and helps to differentiate IBDfrom Irritable Bowel Syndrome (IBS). Moreover, a recent test is developed byCenter for Infection and Immunity at University of Columbia in March 2018,extends a window for accurate detection of Zika infection, which is complexwith molecular diagnostics procedures.
* The sample copy includes: Report Summary, Table of Contents,Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1505
The new ZIKV-NS2B-concat ELISA isa faster, less expensive blood test, and clinical tool for accurate detectionof Zika from weeks to months after onset of infection facilitating a powerfultool for the clinicians to make quick decisions for their patients. In July2015, Bio-Rad Laboratories, Inc. received the U.S. Food and Drug Administrationpre-market approval for BioPlex 2200 HIV Ag-Ab assay, which is the company'sfifth generation HIV diagnostic test that produced efficient diagnostic testresults for HIV.
Browse 42 Market Data Tables and36 Figures spread through 170 Pages and in-depth TOC on “Enzyme LinkedImmunosorbent Assay (ELISA) Market”- by Method (Direct ELISA, Indirect ELISA,Sandwich ELISA and Competitive ELISA), by Application (Vaccine Development,Immunology, Diagnostics, Toxicology, Drug Monitoring & PharmaceuticalIndustry & Transplantation), By Technology (Chemiluminescent, Colorimetric,& Fluorescent), and by Region (North America, Latin America, Europe, AsiaPacific, Middle East, and Africa) - Global Forecast to 2025.
The market players are focusedtowards expansion of their product portfolio and geographic reach by adoptionof inorganic strategies such as mergers and acquisitions to maintain theirpositions in the market. For instance, in March 2017, Thermo Fisher Scientific,Inc. acquired Core Informatics and added it to analytical Instruments segmentto strengthen its existing informatics solutions and bio production offerings.Furthermore, the company players are also focusing on research and developmentfor introducing novel ELISA assays and test kits in to the market to stand outand retain their positions in the market. For instance, in August 2016, ALPCO introducednew and improved, highly specific Total Adiponectin and HMW & TotalAdiponectin ELISAs, this colorimetric assays provides researchers with the confidenceto measure adiponectin.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/enzyme-linked-immunosorbent-assay-market-1505
Key Takeaways of Enzyme LinkedImmunosorbent Assay (ELISA) Market:
The global Enzyme LinkedImmunosorbent Assay (ELISA) Market is expected to exhibit a CAGR of 5.1% overthe forecast period, owing to increasing incidence of infectious diseasescoupled with rising adoption of cost-effective diagnostic solutions
Among method segment, theindirect ELISA segment dominates the global ELISA market, owing to highsensitivity and flexibility offered by the method for determination ofconcentration of a target substance in a sample
Among technology, diagnosticssegment held dominant position in the global ELISA market, owing to potentialof the assay to detect wide variety of disease in human and screen large numberof samples
Among region, North America isexpected to dominate the global Enzyme Linked Immunosorbent Assay (ELISA) Market,owing to introduction of innovative solutions in market to overcome issuesfaced by the clinical facilities and other users
The key players operating inglobal Enzyme Linked Immunosorbent Assay (ELISA) Market include Bio-RadLaboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc.,Biomerieux S.A., Alpco, BioLegand, Inc., Zeus Scientific, Inc., and ShenzhenYHLO Biotech Co., Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1505
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
